Raajit K. Rampal, MD, PhD, discusses JAK inhibitor choice in cytopenic myelofibrosis, emerging combinations, and anemia-directed agents.
Blood Cancer Awareness Month: Evolving JAK Inhibitor Considerations in Myelofibrosis
Experts outline evolving considerations for the use of JAK inhibitors in patients with myelofibrosis.
Gabriela S. Hobbs, MD, discusses how to distinguish proliferative from cytopenic myelofibrosis and the role of risk stratification.
Gabriela Hobbs, MD, explains the importance of risk assessment and using disease factors to drive management approaches in myelofibrosis.
Aaron Gerds, MD, MS, discusses how platelet count and anemia guide JAK inhibitor selection for patients with myelofibrosis.
Aaron Gerds, MD, outlines how cytopenias affect patients with myelofibrosis and how these can help drive JAK inhibitor selection.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
VIR-5500 Receives FDA Fast Track Designation in mCRPC
3
Iberdomide Plus Daratumumab/Dexamethasone Yields Significant PFS Benefit in R/R Myeloma
4
FDA Approves Atezolizumab Plus Chemo for Stage III dMMR Colon Cancer
5